

## IN THE CLAIMS

Please AMEND the claims as follows:

1-36. (Cancelled)

37. (Currently Amended) A ~~purified compound~~ fusion protein comprising a first binding domain and a second binding domain, wherein said first binding domain binds ~~one for a tumor-specific~~ molecule selected from the group consisting of AML1-ETO, BCR-Abl, PML-RARalpha, PLZF-RARalpha, ~~MLL~~ and EWS-FLI ~~fusion protein~~ and ~~[[a]]~~ said second binding domain ~~[[to]]~~ effects dyslocalization of said ~~tumor-specific~~ molecule, wherein said dyslocalization is to a site where said ~~tumor-specific~~ molecule is not normally present in tumor cells.

38. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the dyslocalization inhibits the growth of a tumor cell expressing said ~~tumor-specific~~ molecule.

39. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the dyslocalization induces apoptosis in a tumor cell expressing said ~~tumor-specific~~ molecule.

40. (Canceled)

41. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the ~~tumor-specific~~ molecule is a peptide, oligopeptide, protein, or a fusion protein affects survival of the tumor cell.

42. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the first binding domain has a binding affinity of  $10^{-5}\text{M}$  to  $10^{-12}\text{M}$  for said ~~tumor-specific~~ molecule.

43. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the first binding domain has a binding affinity of  $10^{-7}$  M to  $10^{-9}$  M for said ~~tumor-specific~~ molecule.

44. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the ~~tumor-specific~~ molecule is not present in healthy cells or is present in another form relative to healthy cells.

45. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the ~~tumor-specific~~ molecule is a fusion protein.

46. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the ~~tumor-specific~~ molecule is AML1-ETO.

47. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the ~~tumor-specific~~ molecule comprises a DNA binding domain, a signal peptide, kinase activity, chromatin-modulatory properties, protein-protein interaction domains or transcriptional properties.

48. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the second binding domain binds the ~~tumor-specific~~ molecule to a nucleic acid sequence which regulates the transcription of a gene.

49. (Currently Amended) The ~~purified compound~~ fusion protein of claim 48, wherein said transcription is activated or inhibited.

50. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the first binding domain comprises the peptide sequence of the c-myb DNA binding domain.

51. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein the first binding domain comprises the peptide sequence of the AML-1 binding domain of the myeloid elf like factor.

52. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein said second binding domain comprises the peptide sequence of the c-myb DNA binding domain and said first binding domain comprises the peptide sequence of the AML-1 binding domain of the myeloid elf like factor.

53. (Currently Amended) The ~~purified compound~~ fusion protein of claim 52, wherein the compound has the sequence shown in SEQ ID NO: 1.

54-60. (Canceled)

61. (Withdrawn- currently amended) A method of treating tumors comprising administering to a patient in need thereof a ~~compound~~ fusion protein of claim 37, ~~a nucleic acid of claim 54, a vector of claim 56, or a host cell of claim 57.~~

62. (Withdrawn) The method of claim 61, wherein the tumor is leukemia.

63. (Withdrawn) The method of claim 61, wherein the tumor is acute myeloid leukemia.

64. (Withdrawn- currently amended) A method for the preparation of a ~~compound~~ fusion protein of claim 37, in which the ~~peptide or~~ fusion protein is recombinantly expressed or obtained by protein synthesis.

65-72. (Canceled)

73. (Withdrawn) A method for the preparation of a medicament, comprising the steps of:

(a) identifying a compound suitable for the treatment of tumors by a method of claim 64;

- (b) preparing the compound by synthesis or recombinantly; and
- (c) formulating the compound to give a medicament.

74. (Withdrawn) The method of claim 73, wherein the medicament is suitable for the treatment of tumors.

75. (Withdrawn) The method of claim 73, wherein the medicament is suitable for the treatment of leukemia.

76. (Withdrawn) The method of claim 73, wherein the medicament is suitable for the treatment of acute myeloid leukemia.

77. (Currently Amended) The ~~purified compound~~ fusion protein of claim 37, wherein said second binding domain to effect dyslocalization is a DNA binding domain.